Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 9, pp 411–419 | Cite as

Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use

  • Katherine A. Lyseng-Williamson
Adis Drug Q&A
  • 39 Downloads

Abstract

Amphetamine extended-release oral suspension (Adzenys ER™) and extended-release orally disintegrating tablets (Adzenys XR-ODT®) are easy-to-administer, long-acting, and convenient CNS stimulant options for treating attention-deficit hyperactivity disorder (ADHD) in children aged ≥ 6 years, adolescents, and adults. The bioavailability of d- and l-amphetamine with Adzenys ER™ suspension and XR-ODT® is equivalent to that of a corresponding dose of the reference product [i.e. mixed amphetamine salt extended-release capsules (MAS ER)], which has well-established efficacy, tolerability, and safety profiles. As Adzenys ER™ suspension/XR-ODT® contain both immediate- and extended-release amphetamine particles, plasma concentrations of d- and l-amphetamine increase rapidly, remain relatively stable for several hours, then slowly decline, allowing for once-daily administration. The use of Adzenys ER™ suspension/XR-ODT® may be of particular benefit in individuals who require a rapid onset and prolonged reduction in ADHD symptoms, as well as those who have difficulty swallowing tablets or capsules whole (neither formulation requires swallowing whole tablets/capsules, and both may be taken without regard to food).

Notes

Acknowledgements

The manuscript was reviewed by: A.C. Childress, Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA; R.H. Howland, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA; A.S. Poulton, Sydney Medical School Nepean, The University of Sydney, and Department of Paediatrics, Nepean Hospital, Penrith, NSW, Australia; B.J. Warren, College of Nursing, The Ohio State University, Columbus, OH, USA. During the peer review process, the manufacturer of Adzenys ER™/XR-ODT® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Funding

The preparation of this review was not supported by any external funding.

Compliance with ethical standards

Conflict of interest

K.A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.CrossRefGoogle Scholar
  2. 2.
    Danielson ML, Visser SN, Chronis-Tuscano A, et al. A national description of treatment among United States children and adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2018;192(240–246):e1.Google Scholar
  3. 3.
    Jain R, Jain S, Montano CB. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2017.  https://doi.org/10.4088/PCC.17nr02153.CrossRefPubMedGoogle Scholar
  4. 4.
    Banaschewski T, Becker K, Döpfner M, et al. Attention-deficit/hyperactivity disorder. Dtsch Arztebl Int. 2017;114(9):149–59.PubMedPubMedCentralGoogle Scholar
  5. 5.
    National Collaborating Centre for Mental Health (UK). Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE guideline no. 87. Leicester (UK): British Psychological Society; 2018.Google Scholar
  6. 6.
    Santosh P. Stimulant medication to treat attention-deficit/hyperactivity disorder. BMJ. 2017;358:j2945.  https://doi.org/10.1136/bmj.j294.CrossRefPubMedGoogle Scholar
  7. 7.
    Mattingly GW, Wilson J, Rostain AL. A clinician’s guide to ADHD treatment options. Postgrad Med. 2017;129(7):657–66.CrossRefGoogle Scholar
  8. 8.
    Jain R, Katic A. Current and investigational medication delivery systems for treating attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2016.  https://doi.org/10.4088/PCC.16r01979.CrossRefPubMedGoogle Scholar
  9. 9.
    Adzenys ER (amphetamine) extended-release oral suspension: US prescribing Information. Grand Prairie (TX): Neos Therapeutics, Inc.; 2017.Google Scholar
  10. 10.
    Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII: US prescribing Information. Grand Prairie (TX): Neos Therapeutics, Inc.; 2017.Google Scholar
  11. 11.
    Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol. 2008;28(3 Suppl 2):S39–45.CrossRefGoogle Scholar
  12. 12.
    Sikes C, Stark JG, McMahen R, et al. A single-dose, two-way crossover, open-label bioequivalence study of an amphetamine extended-release oral suspension in healthy adults. J Atten Disord. 2017:1087054717743329.  https://doi.org/10.1177/1087054717743329.
  13. 13.
    Stark JG, Engelking D, McMahen R, et al. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. Postgrad Med. 2016;128(7):648–55.CrossRefGoogle Scholar
  14. 14.
    McCraken JT, Biedernam J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(6):673–83.CrossRefGoogle Scholar
  15. 15.
    Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(2 Pt 1):258–66.CrossRefGoogle Scholar
  16. 16.
    Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–79.CrossRefGoogle Scholar
  17. 17.
    Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–39.CrossRefGoogle Scholar
  18. 18.
    Sikes CR, McMahen RL, Stark JG, et al. Pharmacokinetics of a new amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28(1):29–35.CrossRefGoogle Scholar
  19. 19.
    Sikes C, Stark JG, McMahen R, et al. Pharmacokinetics of a new amphetamine extended-release oral liquid suspension under fasted and fed conditions in healthy adults: a randomized, open-label, single-dose, 3-treatment study. Clin Ther. 2017;39(12):2389–98.CrossRefGoogle Scholar
  20. 20.
    Stark JG, Engelking D, McMahen R, et al. Pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(3):216–22.CrossRefGoogle Scholar
  21. 21.
    Newcorn JH, Stark JG, Adcock S, et al. A randomized phase I study to assess the effect of alcohol on the pharmacokinetics of an extended-release orally disintegrating tablet formulation of amphetamine in healthy adults. Clin Ther. 2017;39(8):1695–705.CrossRefGoogle Scholar
  22. 22.
    McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(6):530–8.CrossRefGoogle Scholar
  23. 23.
    Ambrosini PG, Salle FR, Lopez FA, et al. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD. Curr Med Res Opin. 2006;22(2):427–40.CrossRefGoogle Scholar
  24. 24.
    Biederman J, Spencer TJ, Wilens TE, et al. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):16–25.CrossRefGoogle Scholar
  25. 25.
    Findling RL, Bierderman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147(3):348–54.CrossRefGoogle Scholar
  26. 26.
    Chavez B, Sopko MA Jr, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009;43(6):1084–95.CrossRefGoogle Scholar
  27. 27.
    Rashid MA, Lovick S, Llanwarne NR. Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. Fam Pract. 2018;35(2):142–50.CrossRefGoogle Scholar
  28. 28.
    Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations